Given that the frequency of SLC26A4 mutations in Korean patients with EVA is >90%, it is reasonable to perform TBCT for discriminating between patients with hearing loss due to SLC26A4 mutations and those with NSHL due to other AR mutations9. The gene discussed is AR; the disease is hearing loss disorder.